• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
DNA Probes-Based Diagnostics - Global Business Strategic Report Product Image

DNA Probes-Based Diagnostics - Global Business Strategic Report

  • Published: May 2012
  • Region: Global
  • 493 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in US$ Million by the following Application Areas: Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Becton, Dickinson & Company, Beckman Coulter, Inc., bioMérieux, Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, QIAGEN, Roche Diagnostics, and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

DNA PROBES-BASED DIAGNOSTICS

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Infectious Diseases I-4
Cancer I-4
Genetic Predisposition I-4
Identity/Forensics I-4
Molecular HLA Testing I-4
Other Diagnostic Applications I-4

II. Executive Summary

1. MARKET DYNAMICS II-1
Industry Overview II-1
DNA Probes: Robust Growth Ahead II-1
Decoding the Genetic Puzzle II-1
Advantages of DNA-Probe Tests II-2
Growth Drivers in a Nutshell II-2
Growth Inhibitors in a Nutshell II-2
Genetic Profiling of Pathogens: A Road Less Traveled II-3
Roche's Entry into the Hall of Molecular Fame II-3
DNA Technology: An Evolutionary Scan II-4
An Era of Excellence: Tracking Landmark Breakthroughs in DNA
Diagnostics II-4
Opportunities II-5
Market Trends/Issues II-6
DNA Tests: Finding Use in Numerous Applications II-6
World's Aging Population Drives the Popularity of DNA-Probe
Tests II-6
Reimbursements: “Under the Umbrella” II-6
Evolution of New & Virulent Infectious Agents II-7
The Enlightened Consumer of the 21st Century II-7
Challenges In Widespread Deployment of DNA Based Diagnostics II-7
Miniaturization: An Uphill Task II-7
Improvements in Assay Capabilities II-8
Information Handling & Processing: The Soft Side of Diagnostics II-8
Integration: The Ultimate Challenge II-8
The United States: Unraveling the Country's Edge in DNA based
Diagnostics II-9

2. DNA PROBES-BASED DIAGNOSTICS - A PRIMER II-10
Diagnostic Gene Detection Products II-10
Molecular Diagnostics: A Powerful Disease Detection Tool II-10
DNA Probes-Based Products II-11
Direct Detection of Target Sequence II-11
Nucleic Acid Amplification II-11
Gene Detection Using DNA Chips II-11
Gene Detection by DNA Sequencing II-12
The Dynamics of Key Enabling Technologies II-12
In Situ Hybridization II-12
PCR: Polymerase Chain Reaction II-12
Chemiluminescence II-13
Gen-Probe Tigris II-13
DNA Chips II-13
Key Players II-13
Players in Molecular Diagnostics Market II-13
Molecular Diagnostics - A Primer II-14
Implications for Clinical Diagnostics II-14
Need of the Hour II-14
Molecular Diagnostics: Marking the Convergence of Numerous
Technologies II-14
Impact of the Human Genome Project II-15
Molecular Diagnostics: Domain of the Developed Countries II-15
“Tailored Patient Management”: An Epitomized Future of
Molecular Diagnostics II-15
Futuristics: A Rumination II-15

3. PRODUCT OVERVIEW II-17
Background II-17
Gene Probe Technology II-17
What is DNA? II-17
DNA Probes II-17
Miniaturization: A Revolutionary Method in DNA Analysis II-18
Gene Chip Technology II-18
DNA Chips II-18
Chromosome Painting Probes II-18
Diagnostic Applications Based on DNA Probes: An Overview II-19
Infectious Diseases II-19
Respiratory Tract Infections II-19
Diagnosis of Mycoplasma II-19
DNA Probes to Detect Legionella Pneumophila II-19
Detecting Tuberculosis Through Rapid Diagnostic Tests II-19
How the Technique Works II-20
Limitations II-20
Sexually Transmitted Diseases (STDs) II-20
HIV II-20
HTLV-1 Testing II-20
Hepatitis Testing II-20
Chlamydia DNA Probes II-21
Detection of Intestinal Parasites II-21
Entamoeba Histolytica II-21
Salmonella II-21
Identity/Forensics II-21
DNA Profiling: A Key Forensic Tool II-21
DNA-Based Forensic Diagnostics II-22
Tracing Human Origins II-22
Genetic Predisposition II-22
Molecular HLA Testing II-22
Human Leukocyte Antigen (HLA) Typing II-22
Cancer Testing II-23
Cancer: A Deadly Disease Afflicting Millions II-23
Slow Detoxifiers: Potential Cancer Candidates II-23
Improving Cancer Surgery Through Diagnostic Tests II-23
Types of Cancer II-24
Chronic Lymphocytic Leukemia (CLL) II-24
Breast Cancer II-24
PCR Screening Technology for Breast Cancer II-24
Eye Cancers II-24
DNA Probes to Detect Retinoblastoma II-24
Others II-24
The Ames test II-25
Genetic Testing II-25
Other Diagnostic Applications II-25
Cystic Fibrosis II-25
Malaria Testing II-26
Detection of Multidrug Resistance II-26
Bacterial Resistance to Antibiotics II-26
DNA Probes for Agriculture II-26

4. PRODUCT INTRODUCTIONS/INNOVATIONS II-27
LifeTechnologies Launches Applied Biosystems AutoMate Express™ II-27
OralDNA Labs™ Launches Two Dental Molecular Tests II-27

5. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-28
Luminex Molecular Introduces New xTAG™ Respiratory Viral Panel II-28
Gen-Probe Introduces Aptima HPV Assay in Europe II-28
Genzyme Genetics Introduces Prenatal Diagnosis and Carrier
Testing II-28
Affymetrix Launches New Cytogenetic Solution II-29
Genekam Biotech Develops New Commercial DNA-Test to Detect
Bird Flu II-29
Seegene Launches Innovative DNA Test to Detect HPVs II-30
deCODE Introduces deCODE T2 II-30
InterGenetics Introduces OncoVue II-30
bioMérieux Unveils VIDAS C II-30
bioMérieux Unveils NucliSENS EasyQ HPV II-31
Applied Biosystems Launches SOLiD System II-31
bioMérieux Introduces VIDAS® NT-proBNP II-31
Abbott Molecular Rolls Out Six DNA Probes II-32
PerkinElmer Launches Two New Multiplexing Platforms for
Genomic Research II-32
Kreatech Introduces First Complete Whole Genome Amplification Kit II-32
Relative Genetics Introduces DNA Testing Services II-33
Sorenson Launches Over-the-counter Paternity Test Kits II-33
Kimball Genetics Introduces Warfarin Sensitivity DNA Test II-34
bioMérieux Introduces TEMPO EB II-34
Gen-Probe Launches PCA3 Assay II-34
Genzyme Launches New KRAS Mutation Analysis II-34
BD Launches New BD Viper™ System for Automating Molecular
Diagnostic Testing Process II-35
Affymetrix Unveils New GeneChip® Scanner with Higher Capacity
Scanning II-35
Genzyme Introduces EGFR Mutation Assay for Detecting Mutations II-35

6. RECENT INDUSTRY ACTIVITY II-36
Danaher Acquires Beckman Coulter II-36
QIAGEN Partners with Genome Diagnostics II-36
ZyGEM Snaps Up MicroLab Diagnostics II-36
Metropolis Healthcare Partners with DDC II-37
China Medical Technologies Obtains SFDA Approval II-37
Nanobac Inks Merger Agreement with Eureka Genomics II-37
Genzyme Enters into Licensing Agreement with Moffitt Cancer
Center II-38
Xceed Molecular Offers Gen-Probe License for Flow-Thru Chip®
Technology II-38
Dako Denmark's TOP2A FISH pharmDx Receives FDA Approval II-38
Roche Diagnostics Receives Approval for Elecsys Anti-HCV Assay II-39
bioMérieux and FIND Ink Memorandum of Understanding II-39
BD Establishes Second Production Facility in China II-39
Shanghai Kehua Bio-engineering and bioMérieux Establish Joint
Venture II-39
Quidel to Enter into Alliance with bioMérieux II-40
Beckman Coulter Bags Rights to Hepatitis C Virus Test from
Siemens II-40
Affymetrix Enters into Partnership with Pathwork Diagnostics II-41
Luminex Signs Distribution and Sales Agreement with Abbott II-41
Gen-Probe to Acquire Innogenetics II-42
Biocept to Introduce I.D.Rh(D) II-42
DNA Testing Systems and DNAPrint Genomics Sign Sales Agreement II-42

7. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-44
Siemens Acquires Dade Behring II-44
Sorenson Genomics Acquires Identigene II-44
BioServe Takes Over Genomics Collaborative II-44
Illumina Acquires Solexa II-45
QIAGEN to Merge With eGene II-45
NorDiag Acquires Genpoint II-45
Cepheid Takes Over Sangtec Molecular Diagnostics II-46
3M Enters into Collaboration with Gen-Probe II-46
Luminex Corporation Completes Acquisition of Tm Bioscience II-46
Ventana Medical Systems and C-Path to Collaborate with NCI and
FDA II-47
Ipsen and bioMérieux Enter into Theragnostics Agreement II-47
Celera Acquires Atria Genetics II-48
Celera Acquires Berkeley HeartLab II-48
Beckman Coulter Enters into Partnership II-49
Affymetrix Partners with IPSOGEN for In-Vitro Diagnostic
Cancer Testing II-49
Ventana Medical Systems Collaborates with Genentech II-49
Siemens Medical Solutions Acquires Bayer's Diagnostic Division II-50
Orchid Cellmark Acquires ReliaGene Technologies II-50
GATC Enters into Collaboration for Developing DNA-based
Diagnostic Test II-50
Genetic Solutions and Catapult Merge to Establish Catapult
Genetics II-51
Grant Life Sciences Signs MoU with Alphagenics Diaco
Biotechnologies II-51
Gen-Probe and Millipore Ink Agreement to Market MTC-NI Test II-52
QIAGEN Acquires Digene Corporation II-52
BD Diagnostics and Quest Diagnostics Sign Agreement for BD
Viper™ System II-53
Enzo Biochem Plans to Produce Single Copy DNA Probes II-53
Affymetrix Signs Two Agreements with Sysmex II-53
Affymetrix and Partners HealthCare Enter into Collaboration II-54
Affymetrix and Epigenomics Enter into an Agreement II-54
Roche Introduces Elecsys TORCH Assays II-55
QIAGEN to Take Over Gentra II-55
LGC Acquires AGOWA to Extend German Operations II-55
ENZ Receives Patent for Phosphate Labeling for Medical
Research & DNA Diagnostic Products II-56
TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit II-56
Toshiba Licenses Electrochemical Detection Technology to Antara II-56
Affymetrix Licenses Multiple Patents to Invitrogen II-57
Abbott Enters into Agreement with ALSI for Licensing ProGRP
Biomarker II-57
QIAGEN in Protein Crystallography Co-Marketing Agreement with
ActiveSight II-57
Warnex Acquires Pro-DNA Diagnostic II-58
Celera Genomics Gains Complete Ownership of Celera Diagnostics II-58
Gen-Probe Licenses Exclusive Rights for Diagnostic Tests
Development from University of Michigan II-58
QIAGEN Enters into Licensing Agreement with Applied Biosystems
for Real-Time PCR Technologies II-59
IGC Collaborates with Roche for Cancer Biomarker Discovery II-59
Affymetrix Acquires ParAllele BioScience II-59
QIAGEN Enters into Distribution Agreement with Osmetech
Molecular Diagnostics II-60
GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp. II-60
Gen-Probe Obtains FDA Approval for Marketing APTIMA II-60
Gen-Probe Signs Purchasing Agreement with Roche II-60
MP Biomedicals Acquires Qbiogene II-61
Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test II-61
Ventana Launches ISH Tests II-61

8. FOCUS ON SELECT GLOBAL PLAYERS II-62
Abbott Molecular (US) II-62
Affymetrix, Inc. (US) II-62
Becton, Dickinson & Company (US) II-62
Beckman Coulter, Inc. (US) II-63
bioMérieux (France) II-63
Celera Group (US) II-63
Gen-Probe Incorporated (US) II-64
Genzyme Corporation (US) II-64
Luminex Molecular Diagnostics (Canada) II-64
QIAGEN (US) II-64
Roche Diagnostics (Switzerland) II-65
Siemens Healthcare Diagnostics, Inc. (US) II-65

9. GLOBAL MARKET PERSPECTIVE II-66
Table 1: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
American Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-66

Table 2: World Historic Review for DNA Probes-based
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Latin American Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-67

Table 3: World 15-Year Perspective for DNA Probes-based
Diagnostics by Geographic Region - Percentage Breakdown of
Revenues for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin American Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-68

Table 4: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics (Infectious Disease Diagnosis) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin American Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-69

Table 5: World Historic Review for DNA Probes-based
Diagnostics (Infectious Disease Diagnosis) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin American Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) II-70

Table 6: World 15-Year Perspective for DNA Probes-based
Diagnostics (Infectious Disease Diagnosis) by Geographic
Region - Percentage Breakdown of Revenues for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
American Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) II-71

Table 7: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics (Cancer Diagnosis) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan) and Latin American Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-72

Table 8: World Historic Review for DNA Probes-based
Diagnostics (Cancer Diagnosis) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Latin American Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) II-73

Table 9: World 15-Year Perspective for DNA Probes-based
Diagnostics (Cancer Diagnosis) by Geographic Region -
Percentage Breakdown of Revenues for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Latin American
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-74

Table 10: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics (Genetic Predisposition Diagnosis) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin American Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-75

Table 11: World Historic Review for DNA Probes- based
Diagnostics (Genetic Predisposition Diagnosis) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin American Markets Independently Analyzed with
Annual Revenue Figures Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) II-76

Table 12: World 15-Year Perspective for DNA Probes- based
Diagnostics (Genetic Predisposition Diagnosis) by Geographic
Region - Percentage Breakdown of Revenues for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
American Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) II-77

Table 13: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics (Identity/Forensics Diagnosis) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin American Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-78

Table 14: World Historic Review for DNA Probes- based
Diagnostics (Identity/Forensics Diagnosis) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Latin American Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) II-79

Table 15: World 15-Year Perspective for DNA Probes-based
Diagnostics (Identity/Forensics Diagnosis) by Geographic
Region - Percentage Breakdown of Revenues for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
American Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) II-80

Table 16: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics (Molecular HLA Testing) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan) and Latin American Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-81

Table 17: World Historic Review for DNA Probes-based
Diagnostics (Molecular HLA Testing) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Latin American Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) II-82

Table 18: World 15-Year Perspective for DNA Probes-based
Diagnostics (Molecular HLA) by Geographic Region - Percentage
Breakdown of Revenues for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan) and Latin American Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-83

Table 19: World Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics in Others Types of Diagnosis by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin American Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-84

Table 20: World Historic Review for DNA Probes-based
Diagnostics in Others Types of Diagnosis by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
and Latin American Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) II-85

Table 21: World 15-Year Perspective for DNA Probes- based
Diagnostics in Others Types of Diagnosis by Geographic Region -
Percentage Breakdown of Revenues for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Latin American
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-86

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
DNA-Based Diagnostic and Test Market: Progress towards a New
Phase III-1
DNA-Based Diagnostic Tests Picks Up Pace in New Streams III-1
Rise of DNA-Based Home Testing Kits Market III-2
Focus on Select Key Players III-2
B.Market Analytics III-3
Table 22: The US Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-3

Table 23: The US Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity / Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-4

Table 24: The US 15-Year Perspective for DNA Probes- based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-5

2. CANADA III-6
Market Analytics III-6
Table 25: Canadian Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-6

Table 26: Canadian Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-7

Table 27: Canadian 15-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-8

3. JAPAN III-9
Market Analytics III-9
Table 28: Japanese Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-9

Table 29: Japanese Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-10

Table 30: Japanese 15-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-11

4. EUROPE III-12
Market Analytics III-12
Table 31: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-12

Table 32: European Historic Review for DNA Probes- based
Diagnostics by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-13

Table 33: European 15-Year Perspective for DNA Probes-based
Diagnostics by Geographic Region - Percentage Breakdown of
Revenues for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-14

Table 34: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-15

Table 35: European Historic Review for DNA Probes- based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/ Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-16

Table 36: European 15-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-17

4a. FRANCE III-18
Market Analytics III-18
Table 37: French Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-18

Table 38: French Historic Review for DNA Probes- based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/ Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-19

Table 39: French 15-Year Perspective for DNA Probes- based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2011 & 2017 (includes
correspondingGraph/Chart) III-20

4b. GERMANY III-21
Market Analytics III-21
Table 40: German Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-21

Table 41: German Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-22

Table 42: German 15-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-23

4c. ITALY III-24
Market Analytics III-24
Table 43: Italian Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-24

Table 44: Italian Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity / Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-25

Table 45: Italian 15-Year Perspective for DNA Probes- based
Diagnostics by Application Area - Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-26

4d. THE UNITED KINGDOM III-27
Market Analytics III-27
Table 46: The UK Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area -
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-27

Table 47: The UK Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-28

Table 48: The UK 15-Year Perspective for DNA Probes- based
Diagnostics by Application Area - Percentage Breakdown of
Revenues for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-29

4e. REST OF EUROPE III-30
Market Analytics III-30
Table 49: Rest of European Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area - Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-30

Table 50: Rest of European Historic Review for DNA
Probes-based Diagnostics by Application Area - Infectious
Diseases, Cancer, Genetic Predisposition, Identity/
Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-31

Table 51: Rest of European 15-Year Perspective for DNA
Probes-based Diagnostics by Application Area - Percentage
Breakdown of Revenues for Infectious Diseases, Cancer,
Genetic Predisposition, Identity/Forensics, Molecular HLA
Testing, and Others Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-32

5. ASIA-PACIFIC III-33
Market Analytics III-33
Table 52: Asia-Pacific Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area - Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-33

Table 53: Asia-Pacific Historic Review for DNA Probes-based
Diagnostics by Application Area - Infectious Diseases,
Cancer, Genetic Predisposition, Identity/Forensics,
Molecular HLA Testing, and Others Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-34

Table 54: Asia-Pacific 15-Year Perspective for DNA
Probes-based Diagnostics by Application Area - Percentage
Breakdown of Revenues for Infectious Diseases, Cancer,
Genetic Predisposition, dentity/ Forensics, Molecular HLA
Testing, and Others Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-35

6. LATIN AMERICA III-36
Market Analytics III-36
Table 55: Latin American Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area - Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-36

Table 56: Latin American Historic Review for DNA
Probes-based Diagnostics by Application Area - Infectious
Diseases, Cancer, Genetic Predisposition, Identity/
Forensics, Molecular HLA Testing, and Others Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-37

Table 57: Latin American 15-Year Perspective for DNA
Probes-based Diagnostics by Application Area - Percentage
Breakdown of Revenues for Infectious Diseases, Cancer,
Genetic Predisposition, dentity/ Forensics, Molecular HLA
Testing, and Others Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-38

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 79)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 51
Canada 6
Japan 2
Europe 18
France 1
Germany 8
The United Kingdom 3
Italy 1
Rest of Europe 5
Asia-Pacific (Excluding Japan) 2
------------------------------------------

In the medical diagnostics laboratories of the 21st century, the ability to detect nucleic acids and proteins reign supreme. And given the need to rapidly and inexpensively determine the relevant DNA sequence information in a given organism, the potential of DNA probes-based diagnostics is huge. DNA probes also render themselves as a powerful tool for chromosomal mapping of single and multiple copy genes in the haploid genome. This invariably spells out an expansion in its applications in delineation and classification of many genetic diseases. The future envisages a DNA probe, which offers the ability to detect complex interrelationships between multiple gene expression and environmental factors, at the molecular level. This will help in detecting diseases, which are not the result of single-gene, or monogenetic disorders.

In the upcoming years, DNA diagnostic technologies are set to achieve superior efficiencies and improved activity in numerous application areas, including healthcare, biomedical research, toxicology, bioremediation, forensics and personnel identification, environmental monitoring, biomass operations, industrial processing, monitoring of infectious agents, and quality control in the food industry, animal husbandry, and agriculture. Also, the boom in the molecular diagnostics market is beginning to echo downstream into the DNA-probe based diagnostics segment. Further, affluent population and widening health insurance and medical reimbursements are additionally making expensive cutting edge diagnostic tools, such as DNA-based diagnostics, increasingly affordable.

The US represents the largest regional market for DNA Probe-Based Diagnostics market worldwide, as stated by the new market research report on DNA Probes-Based Diagnostics. In the US, the rapid growth of DNA-based diagnostics is leading to the development of new tests for the treatment of non-contagious diseases, such as diseases related to aging or chronic diseases. DNA-based diagnostic testing is rapidly entering the cancer setting as well. Europe trails behind the US, while the Asia-Pacific market is projected to register the fastest compounded annual growth rate of 21% during the analysis period. Infectious Diseases represents the key end-use market for DNA probes-based diagnostics worldwide. However, fastest growth is expected to emerge from Genetic Predisposition.

Despite the positive outlook, the marketplace continues to be plagued by challenges such as miniaturization, parallelization, and automation. In addition to these key challenges, improvements, and procedural refinement needs to be implemented in the areas of sample preparation, assay technology, detection systems, integration, data management and analysis. The culminated effect of all of these variables will help in determining the efficacy of the technology’s application in clinical diagnostics, in the years to come.

Global Industry Analysts ©

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos